Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1999-03-12
2000-10-24
Krass, Frederick
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514165, 514161, 514162, 514248, 514249, 514252, 514253, 514254, 514332, 514333, 514334, 514335, 514354, 514357, 514367, 514368, 514378, 514393, 514394, 514403, 514406, 514415, 514424, 514438, 514468, 514473, 514534, 514538, 514540, 514542, 514551, 514601, 514602, 514603, 514605, 514922, 514301, 514258, A61K 3144, A01N 4106, A01N 4378
Patent
active
061368040
ABSTRACT:
The invention provides a method for treating, preventing, or reducing the risk of developing a condition selected from the group consisting of acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombotic occlusion and reocclusion, restenosis, transient ischemic attack, and first or subsequent thrombotic stroke, in a patient, comprising administering to the patient a therapeutically effective amount of an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, and an antiplatelet agent, or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 5292756 (1994-03-01), Duggan et al.
patent: 5474995 (1995-12-01), Ducharme et al.
patent: 5700816 (1997-12-01), Isakson et al.
patent: 5800385 (1998-09-01), Demopulos et al.
Busch, U., et al., "Interaction of Meloxicam with Cimetidine, Maalox, or Aspirin," J. Clin. Pharmacol., vol. 36, pp. 79-84 (1996).
Ridker, P. M., et al., "Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men," The New England Journal of Medicine, vol. 336, No. 14, (1997) pp. 973-979.
Talley, J. J., "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis--Selective Inhibitors of Cyclooxygenase-2," Exp. Opin. Ther. Patents, 7(1), (1997) pp. 55-62.
"Use of a Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Receptor in . . . ," The New England Journal of Medicine, vol. 330, No. 14, pp. 956-961 (1994).
Krass Frederick
Merck & Co. , Inc.
Parr Richard S.
Winokur Melvin
LandOfFree
Combination therapy for treating, preventing, or reducing the ri does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for treating, preventing, or reducing the ri, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for treating, preventing, or reducing the ri will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1964227